Tag Archives: CPR

PRNews

Frost & Sullivan Acclaims CGI’s Advanced Genomic & Biomarker Technologies That Drive Industry Innovation in Support of Precision Cancer Treatment

CGI’s technologies provide valuable insights across cancer diagnostics through the accurate and sensitive quantitation of clinically relevant genomic signatures & biomarkers from both blood and tissue samples

SANTA CLARA, California, July 26, 2017 /PRNewswire/ — Based on its recent analysis of the precision oncology industry, Frost & Sullivan recognizes Cancer Genetics, Inc. (CGI or the Company) with the 2017 North American Frost & Sullivan Award for Technology Innovation. CGI’s leading-edge technology platforms and comprehensive menu of diagnostic services enhance precision oncology by enabling earlier cancer detection, improving treatment management, and aiding the development of novel cancer therapies. The Company’s genomic products and services not only present diagnostic, prognostic, and theranostic information for routine clinical care, but also facilitate and accelerate drug development programs seeking to deliver targeted, more effective and safer drugs to market more quickly. With its comprehensive suite of both off-the-shelf and proprietary tests, technology-agnostic approach, global infrastructure, and extensive research collaborations, CGI is at the forefront of enabling precision medicine in oncology globally, from bench to bedside.

“CGI has a wide variety of assays for genomic and immuno-oncology related biomarkers, applicable across several therapeutic areas, including hematological malignancies, solid tumors, and hereditary cancers,” said Frost & Sullivan Research Analyst Vandana Iyer. “The Company offers a broad range of laboratory services that provide critical genomic and biomarker information for patient care and for clinical trials being performed by biotech and pharmaceutical companies. CGI’s recent launches of cutting edge tests, its ability to partner with innovative companies, and its extensive research collaborations with leading academic institutions and cancer centers are a testament to the value and depth of CGI’s commitment to driving industry innovation.”

Some of CGI’s prominent and recently launched technologies include:

  • Complete::IO™ is a unique and in-depth flow cytometry panel supporting informed therapeutic decisions and assessment of potential toxicities for novel immuno-oncology (IO) therapies in blood cancers and solid tumors.
  • Focus::Oncomine™ is capable of simultaneously testing DNA and RNA, enabling the detection of various types of genomic alterations in a single workflow that requires minimal sample quantities and boasts a rapid turnaround time. The Focus::Oncomine™ assay can detect thousands of clinically and pharmacologically relevant biomarkers in solid tumors, making it a valuable tool for clinicians and biopharma.
  • Focus::Lymphoma™ is the most comprehensive next generation sequencing (NGS) panel for B-cell lymphomas in the field.  Focus::Lymphoma™, sequences 220 clinically-actionable genes, allowing clinicians to determine the most effective treatment management for patients. Focus::Lymphoma™ is also offered to biotech and pharmaceutical companies to power efficient clinical trials focused on B-cell lymphomas.
  • Focus::Renal™ is a highly-sensitive NGS panel that provides thorough information for the diagnosis, prognosis and therapy selection in renal cancers.  In a single test, Focus::Renal™ is able to detect mutations in 76 renal cancer-related genes, as well as genome-wide copy number changes, and critical single nucleotide polymorphisms (SNPs). Focus::Renal™ is the only NGS panel of its type, as it is disease-focused, and has been developed through collaboration with leading cancer centers and academic institutions, including MSKCC, Cleveland Clinic, Huntsman Cancer Center at University of Utah, and University Hospital of Paris.
  • Liquid::Lung-cfDNA™ is a CLIA-validated, multi-gene NGS panel for lung cancer liquid biopsies. The test can detect lung tumor-derived cell-free DNA (cfDNA) obtained from a single blood draw, and analyzes frequently-mutated SNPs and short indels in 11 genes with significant clinical relevance to non-small cell lung cancer (NSCLC). This groundbreaking assay is highly sensitive, with a limit of detection (LOD) as low as 0.05% or 1 mutant copy of DNA in a background of 2,000 wild-type copies of DNA.
  • Focus::HERSite™ is a hereditary cancer test that focuses on breast and ovarian cancers. The test analyzes the 16 genes most commonly associated with breast and ovarian cancers and provides in-depth coverage of BRCA1 and BRCA2.
  • Oncomine Dx Target Test is the first NGS-based companion diagnostic (CDx) test that simultaneously screens tumor samples for biomarkers associated with 3 FDA-approved therapies for non-small cell lung cancer (NSCLC). CGI is one of the first laboratories, and one of only three in the United States, to offer the Oncomine Dx Target Test.

CGI has established a global footprint with a presence in the United States, India, and China. The Company’s infrastructure, which has been developed through strategic acquisitions, and its unique business model, which incorporates routine clinical testing for cancer patients and fee-for-service solutions for biotech and pharmaceutical companies, have positioned it uniquely for diversified growth and access to the oncology community. These factors have supported the Company’s successful development of a durable business model through which to commercialize its oncology programs and testing capabilities.

“CGI is a technology-agnostic company with comprehensive diagnostic capabilities utilizing various platforms, including next generation sequencing, fluorescence in situ hybridization, immunohistochemistry, microarrays, RT-PCR, and flow cytometry. The Company boasts full NGS capabilities with both Illumina and Thermo Fisher platforms, offering a mix of proprietary panels and off-the-shelf assays,” noted Iyer. “CGI has several ongoing research collaborations with leading oncologists and cancer centers in both solid tumors and hematological malignancies, including kidney cancer, leukemia, non-Hodgkin’s lymphoma, and HPV-associated cancers. The Company constantly strives for diversity and innovation, and has successfully achieved a balance between the two.”

Each year, Frost & Sullivan presents this award to the company that has demonstrated uniqueness in developing and leveraging new technologies, which significantly impact both the functionality and the customer value of new products and applications. The award lauds the high R&D spend towards innovation, its relevance to the industry, and the positive impact on brand perception.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

ABOUT CANCER GENETICS, INC.

Cancer Genetics, Inc. is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. We have established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.
The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State.

For more information, please visit or follow CGI at:

Internet: www.cancergenetics.com
Twitter: @Cancer_Genetics
Facebook: www.facebook.com/CancerGenetics
Media Contact:
Panna Sharma
Cancer Genetics, Inc.
Tel: 201-528-9200
Email: panna.sharma@cgix.com

Investor Relations Contact:
Richard Moyer
Cameron Associates
535 Fifth Ave., New York, NY 10017
Tel: 212-554-5466
Email: richard@cameronassoc.com

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector, and the investment community. Contact us: Start the discussion.

Contact:

Andrea Steinman
P: 210.477.8425
F: 210.348.1003
E: andrea.steinman@frost.com

PRNews

Survey Finds 68% of Healthcare Respondents Not Familiar with Indoor Location Technologies

LONDON, July 26, 2017 /PRNewswire/ — In a recent B2B technology survey of 455 U.S.-based companies across nine verticals, ABI Research finds that only 32% of respondents are familiar with indoor location technologies and their cost saving benefits. The findings show a disconnect between the healthcare industry’s evident need for an asset tracking solution and their willingness to implement one. Only 2% of healthcare respondents had plans to deploy an indoor location solution within the next twelve months.

“The healthcare industry could see significant returns on investment by tracking assets such as infusion pumps across facilities, especially as medical devices become increasingly advanced and more expensive,” says Samuel McLaughlin, Research Analyst at ABI Research. “There is reluctance within healthcare to deploy asset tracking solutions, despite the potential to save both money and lives. Installation expenses can be high if the solution is not compatible with the hospital’s already-existing network infrastructure and regulations. Indoor location vendors must demonstrate they can offer standards-based systems which can support interoperability features, resulting in easier installation and reduced upfront costs.”

Multiple industry sources estimate that between 10% and 20% of hospital inventory is stolen or lost each year.  This could be partly attributed to healthcare personnel favoring certain equipment and keeping it in areas where only they can access it, rather than where it should be stored. Typical assets that might be tracked in a hospital include ventilators, dialysis machines, heart rate monitors, wheelchairs, and IV pumps. One hospital alone has estimated the yearly cost of replacing IV pumps at US$70k.

Adoption of new and emerging technologies has been traditionally slower in healthcare compared to other verticals, often due to funding issues and cost-saving measures at a government or organizational level. “Recent breaches in security in healthcare systems due to antiquated systems across the world should serve as a wake-up call in hospital organizations to embrace emerging technologies sooner rather than later,” concludes McLaughlin.

These findings are from ABI Research’s Industry Survey: Transformative Technology Adoption and Attitudes report. This report is part of the company’s Location Technologies research service, which includes research, data, and analyst insights.

About ABI Research

ABI Research stands at the forefront of technology market research, providing business leaders with comprehensive research and consulting services to help them implement informed, transformative technology decisions. Founded more than 25 years ago, the company’s global team of senior and long-tenured analysts delivers deep market data forecasts, analyses, and teardown services. ABI Research is an industry pioneer, proactively uncovering ground-breaking business cycles and publishing research 18 to 36 months in advance of other organizations. For more information, visit www.abiresearch.com.

Contact Info: 

Americas                               

EMEA/APAC

Deborah Petrara                       

Denise Duffy

Tel: +1.516.624.2558                 

Tel: +44.203.326.0142

pr@abiresearch.com                  

duffy@abiresearch.com
PRNews

Frost & Sullivan Awards Gala Draws in Top Industry Leaders for Prestigious Recognition

Outstanding company achievements recognized at Frost & Sullivan Awards Ceremony

MOUNTAIN VIEW, California, July 20, 2017 /PRNewswire/ — Frost & Sullivan honored recipients at its Excellence in Best Practices Awards Gala held July 19th in Nashville, TN at the Loews Vanderbilt Hotel.

The Best Practices Awards are presented each year to companies that are predicted to encourage significant growth in their industries, have identified emerging trends before they became the standard in the marketplace, and have created advanced technologies that will catalyze and transform industries in the near future.

“Frost & Sullivan’s Awards program has now been recognizing companies for more than fifteen years,” said Jeff Frigstad, Global Sr. Vice President, Best Practices, Frost & Sullivan. “These Awards come from the rigor used by our talented team of 2,000 thought leaders from over 50 global offices working with over 200,000 clients, to locate the best.”

Awarded companies included:

ACI Worldwide – 2017 United States Digital Payments Customer Value Leadership Award

Aprima Medical Software – 2017 United States Ambulatory Revenue Cycle Management Product Leadership Award

AT&T – 2017 United States Business Metro Carrier Ethernet Services Market Leadership Award

AutoGravity Corporation – 2017 North American Digital Automotive Financing Entrepreneurial Company of the Year Award

bioMérieux – 2017 Global Automated Nucleic Acid Extraction New Product Innovation Award

Bio-Microbics, Inc. – 2017 North American Integrated Water Treatment Technology Leadership Award

Cisco Systems – 2017 Global Network Firewall Market Leadership Award

CliniOps – 2017 North American Digitalization of Clinical Trials Technology Leadership Award

CytoSorbents Corporation – 2017 Global Blood Purification Product Leadership Award

DataRPM – 2017 North American Cognitive Predictive Maintenance in Automotive Manufacturing Technology Leadership Award

Drivewyze, Inc. – 2017 North American Weigh Station Bypass Company of the Year Award

Ekahau – 2017 Global Wi-Fi Network Planning, Deployment, Verification & Troubleshooting Customer Value Leadership Award

FourKites, Inc. – 2017 North American Dynamic Supply Chain Tracking Solutions Entrepreneurial Company of the Year Award

Impinj – 2017 North American RFID Solutions in Healthcare Customer Value Leadership Award

INXPO, Inc. – 2017 Global Web Event Services Growth Excellence Leadership Award

IriTech, Inc. – 2017 North American Biometrics-as-a-Service New Product Innovation Award

MercuryGate International, Inc. – 2017 North American Cloud TMS for Retail Product Leadership Award

MobileIron – 2017 North American Enterprise Mobility Management Product Line Strategy Leadership Award

Omnify Software – 2017 North American PLM for the Mid-sized Medical Devices Customer Value Leadership Award 

Oracle – 2017 North American Health Data Warehousing Product Leadership Award

Pilgrim Quality Solutions, Inc. – 2017 North American Enterprise Quality Management Solution for Pharmaceutical Product Leadership Award

Proscia – 2017 Global Cloud-Based Digital Pathology Enabling Technology Leadership Award

Qualys, Inc. – 2017 Global Vulnerability Management Market Leadership Award

Sonus Networks – 2017 North American Enterprise Session Border Controller Company of the Year Award

Spectrum Enterprise – 2017 United States Business Carrier Ethernet Services Competitive Strategy Innovation and Leadership Award

Swissray International, Inc. – 2017 Global Magnetic Resonance Imaging Price/Performance Value Leadership Award

The Sente Group, Inc. – 2017 North American Test Resource Management Software Customer Value Leadership Award

TMEIC – 2016 Global PV Inverter Company of the Year Award

ToolsGroup – 2017 North American Supply Chain Management for Retail & Wholesale Technology Leadership Award

TruTag Technologies, Inc. – 2017 North American Product Authentication Technology Innovation Award

Unisys – 2017 North American Automated Encrypted Network Security Solution Customer Value Leadership Award

Virtual Hold Technology – 2017 North American Contact Center Software New Product Innovation Award

VirtualHealth – 2017 North American Population Health Management Product Leadership Award

Vodafone Group – 2017 European Cloud Communications and Contact Centers Company of the Year Award

Xerafy – 2017 Global RFID Surgical Instrument Tracking New Product Innovation Award

Yamaha Corporation – 2016 Global Tabletop Audio Conferencing Endpoint Growth Excellence Leadership Award

Yokogawa Electric Corporation – 2017 Global Automation Solutions and Services Customer Value Leadership Award

Zang, an Avaya Company – 2017 North American Communications Platforms as a Service New Product Innovation Award

Zendrive – 2017 North American User-Based Insurance Product Leadership Award

Frost & Sullivan’s Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research in order to identify best practices.

For further information about the Awards Gala, please contact a member of the Best Practices Team.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, collaborates with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that could make or break today’s market participants. For more than 50 years, Frost & Sullivan has been developing growth strategies for the global 1000, emerging businesses, the public sector, and the investment community. Contact us: Start the discussion.

Contact:

Estefany Ariza
P: 210.477.8469
F: 210.348.1003
E: estefany.ariza@frost.com

PRNews

Frost & Sullivan Honors Linguamatics for Developing a Best-in-Class NLP-based Data Mining Platform for the Healthcare Industry

I2E makes natural language processing-based text mining intuitive and interactive

SANTA CLARA, California, July 20, 2017 /PRNewswire/ — Based on its recent analysis of the Big Data text analytics market for the healthcare industry, Frost & Sullivan recognizes Linguamatics with the 2017 Global Frost & Sullivan Award for Enabling Technology Leadership. Linguamatics stands out in the natural language processing (NLP) market for its technology expertise and commitment to delivering exceptional value to clients in the US healthcare industry. The highly flexible and scalable Linguamatics Health platform, powered by I2E, is helping healthcare providers and payers to transition to value-based care.

Within the last year, Linguamatics introduced its fifth iteration of I2E, which includes cutting-edge capabilities such as the normalization of concepts and relationships for quick and comprehensive data retrieval regardless of format; advanced range research; and an extraction and search query language (EASL). The EASL can be generated external to the platform to support custom interfaces, queries in a human-readable format, and superior workflow automation.

“Linguamatics I2E is designed to identify the various nuances of language, such as understanding the difference between ‘history of cancer’ and ‘family history of cancer.’ Further, the I2E 5.0 release identifies precise numerical information in context, like the tumor size and medication dosages,” said Frost & Sullivan Transformational Health Principal Industry Analyst Victor Camlek. “The platform can cluster and categorize multiple concepts based on plugged-in terminologies, thesauri, or ontologies. It finds the perfect balance between linguistic context and medical text negation, ensuring that a search of ‘no evidence of pneumonia’ does not result in a diagnosis of ‘pneumonia.'”

Linguamatics also recently introduced the I2E Asynchronous Messaging Pipeline (I2E AMP) to help healthcare professionals find critical clinical insights faster. With I2E AMP, the Linguamatics platform can automate the Big Data mining of streams of data across multiple servers, providing organizations with scalability as their NLP text mining requirements grow.

Linguamatics I2E is highly flexible and can mine data from many types of data sources, including electronic health records (EHRs), clinical trial and news feeds, medical literature, social media, and lifestyle data. The platform can be deployed as an in-house enterprise system, as a value-add enterprise search capability, or as a software-as-a-service (SaaS) on the cloud. In addition to real-time processing of Big Data, I2E also provides powerful linguistic and data exploration techniques that allow patterns of language to be explored and new ontologies to be boot-strapped from basic principles, such as representations of social determinants of health within discharge summaries.

Linguamatics collaborates closely with health systems to incorporate functionalities that reduce physicians’ manual efforts, while providing real-time point-of-care clinical decision support. The platform provides varied inquiry options, ranging from entity extraction to complete linguistic analysis. An entire patient profile can be built using the right combination of smaller queries, and intelligent searches can lead to the creation of smart queries that can be deployed for a larger user base.

“With its flexibility, transparency, and speed, the I2E platform gives users complete control so they can refine searches on-the-go,” noted Camlek. “Query creation is completely configurable, ensuring that clinical users or business users do not need to be NLP or technical experts. Additionally, for advanced searches, an intuitive drag-and-drop graphical interface helps users view and manage the required queries.”

Overall, for developing a technology that a wide range of companies in the healthcare industry can adopt to create better solutions for their customers, Frost & Sullivan is pleased to present Linguamatics with the 2017 Global Frost & Sullivan Award for Enabling Technology Leadership.

Each year, Frost & Sullivan presents this award to a company that has developed a pioneering technology that not only enhances current products but also enables the development of newer products and applications. The award recognizes the high market acceptance potential of the recipient’s technology.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About Linguamatics

Linguamatics transforms unstructured big data into big insights to advance human health and wellbeing. A world leader in deploying innovative natural language processing (NLP)-based text mining for high-value knowledge discovery and decision support, Linguamatics’ solutions are used by top commercial, academic and government organizations, including 18 of the top 20 global pharmaceutical companies, the US Food and Drug Administration (FDA) and US National Cancer Institute, Cancer Research UK, and leading US healthcare organizations.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector, and the investment community. Contact us: Start the discussion.

Contact:

Ana Arriaga
P: 210.247.3823
F: 210.348.1003
E: ana.arriaga@frost.com

PRNews

Frost & Sullivan Lauds eClinicalWorks for Providing Best-in-class RCM Services to a Wide Range of Independent and Hospital-acquired Physician Practices

eClinicalWorks’ large team of skilled professionals and ecosystem partners ensures hassle-free operation of its RCM services

SANTA CLARA, Calif., July 19, 2017 /PRNewswire/ — Based on its recent analysis of the ambulatory revenue cycle management (RCM) market, Frost & Sullivan recognizes eClinicalWorks with the 2017 North American Frost & Sullivan Award for Customer Value Leadership. eClinicalWorks pioneered a cost-effective, streamlined approach to billing in the ambulatory RCM market with its integrated cloud-based solution. For 2.9% of the monthly collection, it offers physicians comprehensive billing solutions, and prevents existing customers of electronic health record (EHR)/patient heath management/hospital management/patient engagement/cloud services from outsourcing billing services to external vendors. eClinicalWorks’ solutions integrate seamlessly with other proprietary health IT applications, allowing key provider executives to measure and monitor billing performance through unified dashboard reporting, powered by predictive financial analytics.


Frost & Sullivan recognizes eClinicalWorks with the 2017 North American Customer Value Leadership Award.

Click here to read the full Award Write Up – http://bit.ly/2uAagpJ

eClinicalWorks’ cloud-based solution boasts an uptime of 99.9% and has achieved a 98% first-pass acceptance for practice claims. It incorporates both the national rules engine, as well as the company’s own rules engine, so that reimbursements are evaluated efficiently and physician practices become eligible for various payer and state incentives.

“The company has assembled progressive technology modules that digitize the entire billing ecosystem end-to-end. It performs patient insurance eligibility assessment in real time, manages denials, investigates reasons for underpayments, periodically updates database rules, and automates the process of claims adjudication,” said Frost & Sullivan Industry Analyst Koustav Chatterjee. “eClinicalWorks’ built in RCM console also allows customers to monitor claims volumes at an enterprise level.”

Significantly, RCM operations largely require professionals with expertise in optimizing billing and collection for the cost incurred during patient care. eClinicalWorks’ highly skilled billing experts and ecosystem-level partners that have high-value technical capabilities in coding compliance, coding validation, bank reconciliation, and collection ensure that customers do not have to seek third-party help.

“eClinicalWorks is also widely popular among physician practices because of its round-the-clock and customer-friendly service. Dedicated account management teams carefully assess customer queries raised for patient registration, claims processing, and final collection, and make sure that payer reimbursement or self-payments made by patients are delivered directly to providers,” noted Chatterjee. “Technology, coupled with custom service capabilities, are helping eClinicalWorks garner optimum success in this service line.”

eClinicalWorks is a proven leader in the US ambulatory EHR market with an estimated market share of 10.2%, second only to Epic with 11.2%. The company offers advanced health IT solutions to almost 125,000 physicians and nurse practitioners, and its various service lines are used by more than 850,000 providers across all 50 US states, and globally in 20 countries.

For its ability to aid physicians with all their RCM needs and comply with regulations, Frost & Sullivan is pleased to present eClinicalWorks with the 2017 North American Frost & Sullivan Award for Customer Value Leadership.

Each year, Frost & Sullivan presents this award to the company that has demonstrated excellence in implementing strategies that proactively create value for its customers with a focus on improving the return on the investment that customers make in its services or products. The award recognizes the company’s inordinate focus on augmenting the value that its customers receive, beyond simply good customer service, leading to improved customer retention, and, ultimately, customer base expansion.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About eClinicalWorks

eClinicalWorks® is a privately held leader in healthcare IT solutions. With more than 125,000 physicians and nurse practitioners using its solutions, customers include ACOs, physician practices, hospitals, community health centers, departments of health, and convenient care clinics. During the past eight years, 16 eClinicalWorks customers have received the prestigious HIMSS Davies Award, honoring excellence in electronic health record implementation. The company is second largest in the country for e-prescribing. Based in Westborough, Mass., eClinicalWorks has additional offices in Austin, New York City, Chicago, California, Georgia, London, India, and Dubai. For more information, please visit www.eclinicalworks.com, Facebook, Twitter or call 866-888-6929.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Contact us: Start the discussion.

Contact:

Samantha Park
P: +1 210.247.2426
F: +1 210.348.1003
E: samantha.park@frost.com

Photo – https://mma.prnewswire.com/media/537159/Frost_Sullivan_eClinicalWorks_Award.jpg

PRNews

Frost & Sullivan Commends Oracle’s Expertly Engineered Unified Healthcare Analytics Platform, Oracle Healthcare Foundation

-Oracle Healthcare Foundation is the ideal tool to support the healthcare industry’s current and future data integration and data quality challenges

SANTA CLARA, California, July 19, 2017 /PRNewswire/ — Based on its recent analysis of the health data warehousing market, Frost & Sullivan recognizes Oracle Health Sciences with the 2017 North American Frost & Sullivan Award for Product Leadership. Stepping out of its IT industry stronghold, Oracle has engineered a highly organized version of its data warehouse, Oracle Healthcare Foundation (OHF), for the special needs of the healthcare industry. The solution’s unified analytics platform processes traditional clinical and claims data, financial and operational data and supply chain, human resources, administrative, and operational functions.


Oracle

Oracle Healthcare Foundation is a feature-rich analytics platform that supports more than 35 subject areas relevant to health data analytics, giving healthcare providers more granular data regarding the requirements of individuals and populations. They can use this data to effect process changes and quality improvement initiatives as well as leverage its out-of–the-box self-service analytics tools to build customized analytics solutions.

“The solution’s comprehensive, scalable, end-to-end platform enables data acquisition, validation, integration, warehousing, and analytics. It encompasses all data types and sources, delivering clinical, financial, administrative, and omics modules,” said Frost & Sullivan Principal Analyst for Digital Health Nancy Fabozzi. “It facilitates rigorous data integration, data governance, and data quality, driving greater engagement and adoption by operations, financial management, and clinical care delivery teams across the healthcare enterprise.”

Oracle Healthcare Foundation can be deployed as a complete or modular solution and as an on-premise, cloud, or hybrid solution, all depending on the customer’s unique needs.

“We strive to provide our customers with a range of capabilities that deliver a solid, stable and reliable core data foundation that will enable them to propel their healthcare businesses forward and scale to their future data analytics needs,” said Jonathan Sheldon, Global Vice President, Oracle Health Sciences.

Oracle understands that scientific advancement is resulting in new complex data types such as genome sequencing that need to be incorporated into the data warehouse and made available for clinical decision making. For this to happen successfully, the data warehouse must have the capacity to expand in a way that keeps the data footprint consistent and not leave any gaps. Oracle has made optimum use of its technology expertise and resources to reduce the amount of time and effort needed to set up and maintain a robust data warehouse.

“A stable data warehouse can reduce the effort required to tie together all of the customer’s data resources, normalize data, map new pieces of data or data types, and so on,” noted Fabozzi. “With Oracle Healthcare Foundation, all of this takes place in one stable solution, automated so that relatively few people are required to maintain it once it is set up. In doing so, Oracle allows its customers to shift essential human resources to higher value analytics activities instead of engaging them in connecting a data feed or finding an appropriate analytics application.”

Oracle strives for a very collaborative relationship with its customers and together, they drive the product roadmap. This partnership ensures that as Oracle builds out the data model and requirements, customers stay informed and the solution always meets their needs.

Each year, Frost & Sullivan presents this award to the company that has developed a product with innovative features and functionality that is gaining rapid market acceptance. The award recognizes the quality of the solution and the customer value enhancements it enables.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About Oracle
The Oracle Cloud delivers hundreds of SaaS applications and enterprise-class PaaS and IaaS services to customers in more than 195 countries and territories while processing 55 billion transactions a day. For more information about Oracle (NYSE:ORCL), please visit us at oracle.com.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector, and the investment community. Contact us: Start the discussion.

Contact:
Estefany Ariza
P: 210.477.8469
F: 210.348.1003
E: estefany.ariza@frost.com

PRNews

Frost & Sullivan Applauds CORAnet™’s Efforts to Strengthen its Brand in the Competitive Mobile Electronic Health Record Market

CORAnet™ Solutions facilitate interoperability across networks and platforms, giving patients and their families ownership and personal control of their medical records

SANTA CLARA, California, July 17, 2017 /PRNewswire/ — Based on its recent analysis of the mobile electronic health record (EHR) market, Frost & Sullivan recognizes CORAnet™ with the 2017 North America Frost & Sullivan Award for Competitive Strategy Innovation and Leadership. CORAnet™ has emerged a successful, cloud-based mobile technology solution provider, offering first responders, doctors, and individual patients 24/7 secure access to personal health records (PHRs). Its advanced software makes possible real-time access to EHR data that is exchangeable along the entire care continuum. This capability is the result of its deep understanding of sophisticated EHR healthcare information technology, health information exchanges, mobile applications, HIPAA and MU3 compliance requirements.

The greater focus on patient engagement due to the shift toward value-based care has heightened the demand for mobile PHR solutions. CORAnet™ has expertly tapped the opportunities in the market by not only delivering novel EHR solutions but also introducing an emergency medicine platform; an ambulatory platform that provides on-demand access to disparate, consolidated and organized PHRs; and a mobile telemedicine platform that offers remote access to care anywhere.

“When using the CORAnet™ solution, individual patients cannot alter any source-identified health information originating from an EHR system. This guarantees data integrity. Users may, however, add or delete diagnosed allergies, thereby safeguarding against contraindications to medications not otherwise annotated,” said Frost & Sullivan Vice President of Global Life Sciences Nitin Naik. “In addition, if the patient wishes to share EHR data using an email address, the system can generate a PDF file that is password protected.”

CORAnet™’s unique mobile solution is enabled by fully interoperable servers that facilitate access to any EHR system, projecting data in a visual, encrypted format. Outstanding features of the CORAnet™ mobile platform include:

  • A patient-facing, EHR-agnostic solution that allows EHR companies, providers, and health facilities to keep their own proprietary data
  • Aggregation of an individual’s PHR from all health system sources into medical data sets such as medical history, x-rays, laboratory results, and plan of care
  • The ability for the patient to update information on vitals, medications, allergies, and dietary supplements consumed

“CORAnet™ has emerged as an innovative technology leader that widens access to PHRs with a system comprising two demonstrative elements: the ability to integrate information from multiple EHR systems, and the ability to deliver an integrated PHR to consumer mobile devices,” said Naik. “These advantages, along with patient engagement capabilities such as appointment setting, reminders, and the option to view and share imaging files, set CORAnet™ apart as an organization that adds significant value in the new field of care collaboration.”

With more sophisticated application providers designing mobile-ready solutions, the mobile “open way” may quickly become the designated entry point for patients and doctors to access personal health data. Frost & Sullivan commends CORAnet™ for delivering a mobile exchange to support interaction, including interoperability, using multiple sensors and monitors.

“Instant access to a patient’s complete health records via CORAnet allows individuals to manage their healthcare, have peace of mind, and can minimize medical errors, hospital readmissions, and reduce costs. For providers, CORAnet is an efficient, economical tool to improve healthcare delivery and outcomes, and compliance with federal Meaningful Use (MU3) mandate for electronic health records (EHR/EMR),” said CORAnet Solutions President & CEO Cora Alisuag.

Each year, Frost & Sullivan presents this award to the company that has leveraged competitive intelligence to successfully execute a competitive strategy that results in stronger market share, competitive brand positioning, and customer satisfaction.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About CORAnet™

CORAnet™ Solutions, Inc. specializes in bringing mobile innovative solutions to the health care industry in the area of health management, electronic health records support, telemedicine and biometrics data predictive analytics.  CORAnet™ addresses the challenge of inefficiencies of health care by providing the interoperability, security, functionality, availability and mobility of health records. Contact us.

Contact:

P: 240 644 1555
E: info@coranetsolutions.com

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Contact us: Start the discussion.

Contact:

Ana Arriaga
P: 210.247.3823
F: 210.348.1003
E: ana.arriaga@frost.com

PRNews

Venus Concept Closes $38 Million Equity Financing to Support Continued Growth Opportunities

TORONTO, July 13, 2017 /PRNewswire/ — Venus Concept Ltd., a privately-held and innovative global aesthetic technology leader, today announced the closing of a $38 million equity investment. The equity investment was led by EW Healthcare Partners along with significant participation from HealthQuest Capital and Madryn Asset Management. This financing will help support the rapid growth of Venus Concept’s industry first and only subscription-based business model, the ongoing expansion and maturation of its 27 direct global offices, and the continued development of products to serve the aesthetic marketplace.

Scott Barry, Managing Director of EW Healthcare Partners, also commented on the investment: “We are pleased to be supporting Dom and the management team of Venus Concept as they continue to successfully expand their product portfolio and services globally. We believe that their differentiated subscription model and unique products positions them well to take full advantage of tailwinds in the non-invasive aesthetic market. We are excited to participate in the growth of the company.”

In conjunction with their investments, EW Healthcare Partners and HealthQuest will each receive one seat on Venus Concept’s board of directors.

Northland Securities, Inc. acted as the sole Placement Agent for this transaction.

About Venus Concept

Venus Concept is a global medical technology company that develops, commercializes, and delivers safe, efficacious, and easy-to-use aesthetic technologies and related practice enhancement services in a unique, industry-disruptive subscription-based business model. Venus Concept’s devices have been designed in cost-effective and proprietary ways that enable the company to expand beyond the aesthetic industry’s traditional markets of dermatology and plastic surgery, and into non-traditional markets such as family practice, general practice, internal medicine, obstetrics and gynecology, and medical spas. Approximately 70 per cent of its devices are sold in non-traditional markets. The company has expanded its subscription platform and is now selling its devices in over 60 countries, including 27 with direct offices. The company now has over 400 global employees whose customer-centric approach has supported the rapid growth of the company. For more information, please visit www.venusconcept.com.

About EW Healthcare Partners

With over $3.0 billion under management, EW Healthcare Partners is one of the largest and oldest growth equity firms pursuing investments in pharmaceuticals, medical devices, healthcare services, and healthcare information technology. Since its founding in 1985, Essex Woodlands has maintained its singular commitment to the healthcare industry and has been involved in the founding, investing, and/or management of over 150 healthcare companies, ranging across sectors, stages, and geographies. The team is comprised of over 20 senior investment professionals with offices in Palo Alto, Houston, New York, and London. For more information, please see www.ewhealthcare.com.

About HealthQuest Capital

HealthQuest Capital makes early growth investments in innovative commercial-stage healthcare companies that are improving both patient outcomes and healthcare economics. Investments focus on medical products, diagnostics, healthcare IT, and technology-enabled healthcare services. HealthQuest Capital is headquartered in Menlo Park, CA with west coast and east coast offices. Learn more at www.healthquestcapital.com.

About Madryn Asset Management, LP

Madryn Asset Management, LP is a leading alternative asset management firm that invests in innovative healthcare companies specializing in unique and transformative products, technologies, and services that create attractive economic opportunities. Backed by a seasoned executive management team, the firm draws upon its diverse expertise and original insights to deliver attractive returns for its limited partners while creating long-term value in support of its portfolio companies.

For further information: Melissa Kang, Phone: (888) 907-0115 ext. 139, Fax: (855) 905-0115, Email: mkang@venusconcept.com

Logo – http://mma.prnewswire.com/media/535368/VCO_StandardLogo_BLACK_Logo.jpg

PRNews

Accomplished technology executive Chris Veator is latest addition to Clarivate Analytics, leading its MarkMonitor business

PHILADELPHIA, July 6, 2017 /PRNewswire/ — Clarivate Analytics, a global leader in providing trusted insights and analytics to accelerate the pace of innovation, today announced that Chris Veator joined the company as President of its MarkMonitor business. Veator will lead the global MarkMonitor team from its San Francisco office.


Chris Veator joins Clarivate Analytics to lead its MarkMonitor business

MarkMonitor is the global leader in online brand protection, and provides advanced technology and expertise that protects the revenues and reputations of the world’s foremost brands. It leads the industry in providing domain management, anti-piracy and anti-fraud solutions to more than half of the Fortune 100.

“With the company’s focus on innovation, I’m excited to join at a time when Clarivate is making a major investment in new technology and analytics that is already in production with 100 MarkMonitor customers,” said Veator.

Prior to this role, Veator was President of Metrostudy, a Hanley Wood company, where he oversaw the rapid growth of the real estate and construction information business. Prior to that, he was Executive Vice President and Global Head of Intellectual Property Services at Thomson Reuters. Veator has also held senior executive roles at CPA Global, OpenText and was the founder and CEO of Artesia Technologies – a Digital Asset Management software company.

“Chris is a high-energy executive and an exciting addition to our team as we focus on building Clarivate Analytics and accelerating its growth,” said Jay Nadler, CEO of Clarivate Analytics. “He has had success both as an entrepreneur and as an “intrapreneur”, driving growth of new initiatives within a corporate setting. I look forward to what Chris will bring to the MarkMonitor business.”

Clarivate Analytics

Clarivate™ Analytics accelerates the pace of innovation by providing trusted insights and analytics to customers around the world, enabling them to discover, protect and commercialize new ideas faster. Formerly the Intellectual Property and Science business of Thomson Reuters, we own and operate a collection of leading subscription-based businesses focused on scientific and academic research, patent analytics and regulatory standards, pharmaceutical and biotech intelligence, trademark protection, domain brand protection and intellectual property management. Clarivate™ Analytics is now an independent company with over 4,000 employees, operating in more than 100 countries and owns well‐known brands that include Web of Science™, Cortellis™, Derwent™, CompuMark™, MarkMonitor® and Techstreet™, among others. For more information, please visit clarivate.com.

Media Contact
Heidi Siegel
Clarivate Analytics
Director, External Relations
+1 215 823 5646 (o)
+1 215 356 4504 (m)
heidi.siegel@clarivate.com